|
|
|
|
|
|
by sam537
755 days ago
|
|
|
The problem here is the potential toxicity of this combination.
In lung cancer for example, the combination of anti-EGFR therapy + pembrolizumab led to deadly pneumonitis (lung inflammation). We want to cure more patients, but we don't want to kill them before their cancer. |
|
|